stoxline Quote Chart Rank Option Currency Glossary
Cerus Corporation (CERS)
2.21  -0.01 (-0.45%)    02-23 16:00
Open: 2.2
High: 2.3
Volume: 799,708
Pre. Close: 2.22
Low: 2.15
Market Cap: 400(M)
Technical analysis
2024-02-23 4:35:38 PM
Short term     
Mid term     
Targets 6-month :  2.83 1-year :  3.31
Resists First :  2.43 Second :  2.83
Pivot price 2.23
Supports First :  1.94 Second :  1.64
MAs MA(5) :  2.26 MA(20) :  2.15
MA(100) :  1.78 MA(250) :  2.11
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  64.5 D(3) :  71.8
RSI RSI(14): 53.8
52-week High :  3.07 Low :  1.21
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ CERS ] has closed above bottom band by 45.7%. Bollinger Bands are 8.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.32 - 2.34 2.34 - 2.35
Low: 2.1 - 2.13 2.13 - 2.15
Close: 2.18 - 2.22 2.22 - 2.25
Company Description

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

Headline News

Tue, 20 Feb 2024
Cerus Corporation to Release Fourth Quarter and Full-Year 2023 Financial Results on March 5, 2024 - Yahoo Finance

Fri, 16 Feb 2024
Cerus Co. (NASDAQ:CERS) Sees Large Increase in Short Interest - MarketBeat

Tue, 06 Feb 2024
What is the Market's View on Cerus Corp (CERS) Stock's Price and Volume Trends Tuesday? - InvestorsObserver

Mon, 05 Feb 2024
Sepio Capital LP Buys 3104062 Shares of Cerus Co. (NASDAQ:CERS) - MarketBeat

Fri, 02 Feb 2024
Will Cerus Corp (CERS) Stay at the Top of the Healthcare Sector? - InvestorsObserver

Mon, 22 Jan 2024
Premarket Mover: Cerus Corporation (CERS) Down 6.25% - InvestorsObserver

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Medical Devices
Shares Out 181 (M)
Shares Float 156 (M)
Held by Insiders 3 (%)
Held by Institutions 74.8 (%)
Shares Short 4,480 (K)
Shares Short P.Month 4,600 (K)
Stock Financials
EPS -0.28
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.27
Profit Margin -32.5 %
Operating Margin -9.2 %
Return on Assets (ttm) -11.1 %
Return on Equity (ttm) -81.1 %
Qtrly Rev. Growth 0.5 %
Gross Profit (p.s.) 0
Sales Per Share 0.84
EBITDA (p.s.) -0.2
Qtrly Earnings Growth 0 %
Operating Cash Flow -30 (M)
Levered Free Cash Flow -11 (M)
Stock Valuations
PE Ratio -8.19
PEG Ratio 0
Price to Book value 8.18
Price to Sales 2.6
Price to Cash Flow -13.47
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android